|
重组人凝血因子 在中国血友病A患者的有效性及抑制物产生的观察 |
| |
ic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5year study of home therapy［J］. Haemophilia, 1999, 5(1):916.
[10] GOUDEMAND J, LAURIAN Y, CALVEZ T, et al. Risk of inhibitors in haemophilia and the type of factor replacement［J］. Curr Opin Hematol, 2006, 13(5):316322.
[11] EWENSTEIN BM, GOMPERTS ED, PEARSON S, et al. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study［J］. Haemophilia, 2004, 10(5):491498.
[12] KEMPTON CL, SOUCIE JM, ABSHIRE TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates[J]. Journal of Thrombosis and Haemostasis, 2006, 4(12):25762581.
[13] SAMANTHA C, GOUW SC, JOHANNA G, et al. Recombinant versus plasmaderived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study［J］. Blood, 2007, 109(11):46934697.
[14] LUSHER J, ABILDGAARD C, ARKIN S, et al. Human recombinant DNAderived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: 上一页 [1] [2] [3] [4] [5] [6] [7] [8] 下一页
上一个医学论文： 白血病患者炎症因子 VEGF表达与易栓状态关系的研究
下一个医学论文： 出血性血小板病患者凝血酶受体GP Ib IX V复合物表达研究
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文